Safety and efficacy of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus
Objective: to study the safety and efficacy of the 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with systemic lupus erythematosus (SLE).Patients and methods. The study included 75 patients with definite diagnosis of SLE at the age of 19–68 years, 10 (13%) of them had high SLE a...
Saved in:
Main Authors: | G. M. Tarasova, B. S. Belov, M. V. Cherkasova, E. A. Aseeva, T. M. Reshetnyak, T. V. Popkova, N. M. Kosheleva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2021-06-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/1148 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
INVESTIGATION OF IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: G. M. Tarasova, et al.
Published: (2018-09-01) -
Immunogenicity, Tolerability, and Clinical Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients with Systemic Lupus Erythematosus
by: G. M. Tarasova, et al.
Published: (2020-08-01) -
Immunogenicity, Safety, and Clinical Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine in Patients With Spondyloarthritis (Preliminary Data)
by: M. M. Baranova, et al.
Published: (2022-04-01) -
Immunogenicity and safety study of 23-valent pneumococcal polysaccharide vaccine revaccination among elderly individuals aged 60–70 years in Shanghai, China
by: Jing Qiu, et al.
Published: (2025-07-01) -
Persistence of antibody to 23-valent pneumococcal polysaccharide vaccine: a 5-year prospective follow-up cohort study
by: Xiang Guo, et al.
Published: (2024-12-01)